Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug-induced steatosis in mice

Hepatology

Volumn 38, Issue 1, 2003, Pages 133-140

  Lettéron, Philippe ^a   Sutton, Angela ^b   Mansouri, Abdellah ^b   Fromenty, Bernard ^b   Pessayre, Dominique ^b  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINEPTINE; AMIODARONE; APOLIPOPROTEIN B; CARRIER PROTEIN; CELL PROTEIN; DOXYCYCLINE; FATTY ACID; LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PIRPROFEN; TETRACYCLINE DERIVATIVE; TIANEPTINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG INDUCED DISEASE; ENDOPLASMIC RETICULUM; FATTY ACID OXIDATION; LIPOPROTEIN SECRETION; MICROSOME; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STEATOSIS;

EID: 0038643426     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50309     Document Type: Article

References (45)

1. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
2. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-69.
3. Shelness GS, Ingram MF, Huang XF, DeLozier JA. Apolipoprotein B in the rough endoplasmic reticulum: translation, translocation and the initiation of lipoprotein assembly. J Nutr 1999;129:456S-462S.
4. Liao W, Yeung SCJ, Chan L. Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum. J Biol Chem 1998;273:27225-27230.
5. Fromenty B, Pessayre D. Inhibition of mitochondrial β-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-154.
6. Le Dinh T, Fréneaux E, Labbe G, Lettéron P, Degott C, Genève J, Berson A, et al. Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1988;247:745-750.
7. Fromenty B, Fisch C, Labbe G, Degott C, Deschamps D, Berson A, Lettéron P, et al. Amiodarone inhibits the mitochondrial β-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990;255:1371-1376.
8. Fromenty B, Lettéron P, Fisch C, Berson A, Deschamps D, Pessayre D. Evaluation of human blood lymphocytes as a model to study the effects of drugs on human mitochondria. Effects of low concentrations of amiodarone on fatty acid oxidation, ATP levels and cell survival. Biochem Pharmacol 1993;46:421-432.
9. Labbe G, Fromenty B, Fréneaux E, Morzelle V, Lettéron P, Berson A, Pessayre D. Effects of various tetracycline derivatives on in vitro and in vivo β-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in mice. Biochem Pharmacol 1991;41:638-641.
10. Geneve J, Labbe G, Degott C, Lettéron P, Fréneaux E, Le Dinh T, Hayat-Bonan B, et al. Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this non steroidal antiinflammatory drug. J Pharmacol Exp Ther 1987;242:1133-1137.
11. Fréneaux E, Labbe G, Lettéron P, Le Dinh T, Degott C, Genève J, Larrey D, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in humans. Possible role in microvesicular steatosis induced by this antibiotic. HEPATOLOGY 1988;8:1056-1062.
12. Fromenty B, Fréneaux E, Labbe G, Deschamps D, Larrey D, Lettéron P, Pessayre D. Tianeptine, a new tricyclic antidepressant metabolized by β-oxidation of its heptanoic side chain, inhibits the β-oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol 1989;38:3743-3751.
13. Breen KJ, Schenker S, Heimberg M. Fatty liver induced by tetracycline in the rat. Dose-response relationships and effect of sex. Gastroenterology 1975;69:714-723.
14. Deboyser D, Goethals F, Krack G, Roberfroid M. Investigation into the mechanism of tetracycline-induced steatosis: study in isolated hepatocytes. Toxicol Appl Pharmacol 1989;97:473-479.
15. Perlemuter G, Sabile A, Lettéron P, Vona G, Topilko A, Samson-Bouma ME, Chrétien Y, et al. Hepatitis virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lioprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185-194.
16. Lettéron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis leads to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200-208.
17. Borensztajn J, Rone MS, Kotlar TJ. The inhibition in vivo of lipoprotein lipase (clearing-factor lipase) activity by triton WR-1339. Biochem J 1976;156:539-543.
18. Lettéron P, Fouin-Fortunet H, Tinel M, Danan G, Belghiti J, Pessayre D, Mechanism for isaxonine hepatitis. I. Metabolic activation by mouse and human cytochrome P-450. J Pharmacol Exp Ther 1984;229:845-850.
19. Lin MCM, Gordon D, Wettereau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res 1995;36:1073-1081.
20. Lin MCM, Li JJ, Wang EJ, Princler GL, Kauffman FC, Kung HF. Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene. FASEB J 1997;11:1145-1152.
21. Navasa M, Gordon DA, Hariharan N, Jamil H, Shigenaga JK, Moser A, Fiers W, et al. Regulation of microsomal triglyceride transfer protein mRNA expression by endotoxin and cytokines. J Lipid Res 1998;39:1220-1230.
22. Pullinger CR, North JD, Teng BB, Rifici VA, de Brito AER, Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin and insulin, and measurement of the mRNA half-life. J Lipid Res 1989;30:1065-1077.
23. Wetterau JR, Lin MCM, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997;1345:136-150.
24. Ingram MF, Shelness GS. Folding of the amino-terminal domain of apolipoprotein B initiates microsomal triglyceride transfer protein-dependent lipid transfer to nascent very low density lipoprotein. J Biol Chem 1997;272:10279-10286.
25. Adeli K, Macri J, Mohammadi A, Kito M, Urade R, Cavallo D. Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells. J Biol Chem 1997;272:22489-22494.
26. Davidson NO, Shelness GS. Apolipoprotein B: mRNA editing, lipoprotein assembly and presecretory degradation. Ann Rev Nutr 2000;20:169-193.
27. Gillian-Daniel DL, Bates PW, Tebon A, Artie AD. Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc Natl Acad Sci U S A 2002;99:4337-4342.
28. Wetterau JR, Gregg RE, Harrity TW, Arbeeny C, Cap M, Connolly F, Chu CH, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998;282:751-754.
29. Wang Y, Tran K, Yao Z. The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. J Biol Chem 1999;274:27793-27800.
30. Hebbachi AM, Gibbons GF. Inactivation of microsomal triglyceride transfer protein impairs the normal redistribution but not the turnover of newly synthesized glycerolipid in the cytosol, endoplasmic reticulum and Golgi of primary rat hepatocytes. Biochim Biophys Acta 1999;1441:36-50.
31. Macri J, Kazemian P, Kulinski A, Rudy D, Aiton A, Thibert RJ, Adeli K. Translocational Status of Apo B in the presence of an inhibitor of microsomal triglyceride transfer protein. Biochem Biophys Res Commun 2000;276:1035-1047.
32. Isselbacher KJ, Scheig R, Plotkin GR, Cualfield JB. Congenital B-lipoprotein deficiency, a hereditary disorder involving a defect in the absorption and transport of lipids. Medicine 1964;43:347-361.
33. Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, Gil CM, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993;365:65-69.
34. Raabe M, Flynn LM, Zlot CH, Wong JS, Véniant MM, Hamilton RL, Young SG. Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc Natl Acad Sci U S A 1998;95:8686-8691.
35. Raabe M, Véniant MM, Sullivan MA, Zlot CH, Björkegren J, Nielsen LB, Wong JS, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knock-out mice. J Clin Invest 1999;103:1287-1298.
36. Berson A, de Beco V, Lettéron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology, 1998;114:764-774.
37. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075.
38. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistty of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Rad Biol Med 1991;11:81-128.
39. Chen J, Schenker S, Frosto TA, Henderson GI. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. Biochim Biophys Acta 1998;1380:336-344.
40. Pessayre D, Mansouri A, Fromenty B. Mitochondrial dysfunction in steatohepatitis. Am J Physiol 2002;282:G193-G199.
41. Yang SQ, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, Diehl AM. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000;378:259-268.
42. Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, Seeff LB, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. HEPATOLOGY 1989;9:679-685.
43. Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol 1987;65:360-364.
44. Lettéron P, Brahimi-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D. Glucocorticoids inhibit mitochondrial matrix acyl-coenzyme A dehydrogenases and fatty acid β-oxidation. Am J Physiol 1997;272: G1141-G1150.
45. Bellringer ME, Rahman K, Coleman R. Sodium valproate inhibits the movement of secretory vesicles in rat hepatocytes. Biochem J 1988;249:513-519.